- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
September 5, 2017
General
On September 5, there was a conversation with Dr. Carl Dieffenbach, the Director of the Division of AIDS (DAIDS) at the NIH’s National Institute of Allergy and Infectious Diseases, about the future of investments in the US National Institutes of Health’s (NIH) HIV clinical trial research networks in the US and internationally.
Every seven years, the NIH reviews the structure and funding of its HIV clinical research networks. This “network recompetition” process involves decisions will help determine the focus and priorities of its HIV clinical trial networks through 2027, as well as the number and structures of the various networks that undertake this research. These are critical questions for advocates to weigh in on—whether you are in the US or not. Learn more with our factsheet.
The webinar included a brief introductory presentation from Dr. Carl Dieffenbach followed by a Q&A session. NIAID is also currently accepting public comments and questions online, so now is your chance!